Statement of total voting rights and shares forming the company's share capital as October 20, 2025

On October 20, 2025, Inventiva, a clinical-stage biopharmaceutical company, announced its statement of total voting rights and shares forming the company’s share capital in accordance with Article R. 22-10-23 of the French Commercial Code. As of this date, Inventiva had 145,951,274 shares outstanding, translating into total gross voting rights of 158,653,570. However, when considering only the net voting rights, which exclude suspended voting rights associated with treasury shares, the figure adjusted to 158,594,019.

Gross voting rights are calculated based on all shares with attached voting rights, including suspended rights that do not contribute to shareholder meetings. This figure is essential for classifications involving threshold crossings, per Article 223-11 of the AMF General Regulations. In contrast, the net voting rights provide a more practical view, indicating the actual voting power available for use during shareholders’ meetings after excluding treasury shares.

Inventiva is publicly traded on the regulated market of Euronext Paris under the ticker IVA (ISIN: FR0013233012), in addition to being listed on the Nasdaq Global Market in the United States. The company specializes in developing small molecule therapies for treating metabolic conditions, particularly investigating its candidate drug, lanifibranor, as part of the pivotal Phase 3 NATiV3 clinical trial targeting patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH).

For further information, investors and media representatives can reach out to Inventiva’s corporate communications team or their healthcare media relations partners via the provided contact details. Visit their official website at www.inventivapharma.com for additional updates.

As of October 20, 2025, Inventiva's Statement of Total Voting Rights and Shares indicates a total of 145,951,274 shares outstanding, with gross voting rights amounting to 158,653,570 and net voting rights at 158,594,019. The slight discrepancy between gross and net voting rights signifies a restrained ability for certain shares to confer voting power, primarily due to treasury shares, which are not exercisable at shareholder meetings.

From a market perspective, this data is vital for gauging shareholder influence and determining thresholds for corporate governance matters. Gross voting rights are useful for determining potential changes in control or significant actions necessitating shareholder approval. The relatively healthy number of total voting rights suggests that Inventiva has ample potential for shareholder engagement, which can be a positive sign for governance transparency and activism.

As a clinical-stage biopharmaceutical firm, Inventiva is focused on developing therapies for metabolic conditions, with its lead candidate, lanifibranor, in a pivotal Phase 3 trial. The market's reception of clinical data and subsequent trial outcomes will be crucial for share price performance moving forward. Investors should keep an eye on upcoming trial results, as successful outcomes could enhance the company’s valuation significantly.

Additionally, the share capital structure reveals that Inventiva is maintaining a solid financial foundation, essential for its research initiatives. Prospective investors should monitor the company's ability to manage dilution risks associated with future financing rounds, especially given the nature of biopharmaceutical development, which often requires substantial capital.

In conclusion, Inventiva presents a compelling investment opportunity, particularly for those looking to capitalize on advancements in biopharmaceutical therapies. However, close attention should be paid to clinical developments and their implications on the share structure and corporate governance.